ReviewInternational journal of molecular sciences2026
Curcumin as a Multi-Target Bioactive Molecule: Mechanistic Insights and Translational Perspectives.
Review in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Nanocurcumin attenuates brain injury in rats with desert dry‑heat‑induced exertional heat stroke by suppressing TLR4/MyD88/NF‑κB signaling.Molecular medicine reports · 2026Article
- Article
- Effects of dietary nanocurcumin on growth, immunity and stress response in European seabass (Dicentrarchus labrax).Journal of comparative physiology. B, Biochemical, systemic, and environmental physiology · 2026Article
- Enhancing Targeted Colorectal Cancer Therapies with Natural Products: Mechanistic Pathways.Biomedicines · 2026Review
- Curcumin in Alzheimer's Disease: From Mechanistic Insights to Translational Challenges and Emerging Curcuminoid Strategies.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Curcumin, a natural polyphenolic compound derived from the curcuma genus, has attracted considerable attention due to its simple chemical structure, favorable safety profile, and broad-spectrum pharmacological activities. This review provides a comprehensive summary of recent advances in curcumin research, with a specific focus on its therapeutic potential in cancer, inflammation, depression, and metabolic disorders, including non-alcoholic fatty liver disease, hypertension, and osteoporosis. It highlights curcumin's modulation of critical signaling pathways, such as PI3K/Akt, NF-κB, JAK/STAT, MAPK/ERK, mTOR, and Wnt/β-catenin, which regulate essential cellular processes, including proliferation, apoptosis, metabolism, and immune response. In various models of solid tumors and hematologic malignancies, curcumin has exhibited potent anti-cancer effects and shows promise in combination with chemotherapy to overcome drug resistance. Moreover, the mechanisms underlying curcumin's effects on inflammation-related diseases and chronic conditions are becoming increasingly well-understood. To address its limitations, such as poor water solubility, rapid metabolism, and low bioavailability, several advanced drug delivery systems-such as nanocarriers, microspheres, and solid dispersions-have been developed to enhance its in vivo stability and targeting efficiency. Beyond its pharmacological applications, curcumin is also employed as a functional additive in food science, particularly in active packaging and food safety testing. In conclusion, curcumin not only serves as a valuable pharmacological probe but also functions as a natural molecular template bridging basic research, formulation innovation, and multidisciplinary translational applications. Future research should focus on optimizing its chemical structure, advancing biosynthesis engineering, and conducting rigorous clinical trials to facilitate its widespread adoption in precision medicine and health interventions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.